Recursion Pharmaceuticals

RXRX

Market cap $1.82B

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.

Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.

Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.

Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven neuromuscular diseases. Recursion Pharmaceuticals utilizes an artificial intelligence OS to accelerate drug discovery across several therapeutic areas.

Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and massive biological datasets to accelerate drug discovery via high-tech collaborations.

Recursion Pharmaceuticals leverages an artificial intelligence platform to decode biology and automate the drug discovery process. Summit Therapeutics is focused on its lead oncology candidate, ivonescimab, aiming to disrupt the standard of care in lung cancer.

Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds.

Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.